

CURRICULUM VITAE

GENERAL

NAME: Helen Marie Pettinati (nee Rimkus)

ADDRESS: Treatment Research Center
3900 Chestnut St.
Philadelphia, PA 19104-6178

TELEPHONE: (215) 222-3200 ext.139

HOME ADDRESS: 106 Antler Court
Fairless Hills, PA 19030

HOME PHONE: (215) 547-0311

DATE OF BIRTH: March 31, 1951

MARITAL STATUS: Married (1973): Joseph Vincent Pettinati, Ed.M., M.B.A.
Daughter (born 8/5/81): Lisa Marie
Daughter (born 11/21/84): Anne Theresa
Son (born 11/21/84): Joseph Charles

PRESENT POSITION

Division Director
Addiction Treatment Research & Medication Development
Center for the Study of Addictions
University of Pennsylvania
Philadelphia, PA 19104

PRESENT ACADEMIC AFFILIATION

Research Professor
Department of Psychiatry
University of Pennsylvania School of Medicine
Philadelphia, PA 19104

EDUCATION

UNDERGRADUATE: Drexel University, Philadelphia
B.S., 1973, Psychology (summa cum laude)

GRADUATE: The Medical College of Pennsylvania, Philadelphia
Ph.D., 1979, Psychiatry/Psychiatric Research

FACULTY APPOINTMENTS

1981-1986 Adjunct-Assistant Professor, Psychiatry
UMDNJ-Robert Wood Johnson Medical School

1986-1995 Adjunct-Associate Professor, Psychiatry

| | |
|----------------|--|
| 1989-1997 | UMDNJ-Robert Wood Johnson Medical School Visiting Faculty, Center of Alcohol Studies, Rutgers University |
| 1995-2002 | Research Associate Professor, Psychiatry, University of Pennsylvania School of Medicine |
| 2003 - Present | Research Professor, Psychiatry, University of Pennsylvania School of Medicine |

PROFESSIONAL AND RESEARCH EXPERIENCE

Research Assistant, Drug and Alcohol Abuse Program, The Medical College of Pennsylvania (Freda Adler, Ph.D.), 1974

Research Assistant, Eastern Pennsylvania Psychiatric Institute (Robert Steppacher, M.D.), 1975

Research Assistant/Associate, Unit for Experimental Psychiatry, The Institute of Pennsylvania Hospital (Martin T. Orne, M.D., Ph.D.), 1975-1979

Coordinator of Research Activities, Research Division, Carrier Foundation, 1979-1981

Member, Institutional Review Board, Carrier Foundation, 1980-1994

Assistant Director, Research Division, Carrier Foundation, 1981-1987

Chair, Executive Committee on Research, Society for Clinical and Experimental Hypnosis, 1981-1983

Chair, Research Workshop of the Society for Clinical and Experimental Hypnosis:
Portland, Oregon, October 13-15, 1981
Indianapolis, Indiana, October 19-24, 1982
Boston, Massachusetts, October 11-12, 1983
San Antonio, Texas, October 22-25, 1984
Chicago, Illinois, September 25, 1986

Member, Research Advisory Committee to the Board of Trustees, Carrier Foundation, 1982-1994

Chair, Scientific Program of the Society for Clinical and Experimental Hypnosis:
Boston, October 11-16, 1983
San Antonio, October 25-27, 1984

Chair, Constitution Committee, Society for Clinical and Experimental Hypnosis, 1985-1986

Treasurer, American Psychological Association, Division 30, 1986-1988

Director of Research, Research Division, Carrier Foundation, 1987-1994

Chairperson, Research Committee, Carrier Foundation, 1987-1994 (Member since 1980)

Member, Steering Committee, Center for Studies of Addiction, University of Pennsylvania, 1987-Present

NIDA Special Review Committee (SRC), Rockville, MD; 1988, 1989, 1991

NIAAA Institutional Review Group (IRG), Clinical and Treatment Research Subcommittee, 1991-1995

Member, Committee on Standardization of Methodology for Clinical Trials of Alcoholism Therapies, Bethesda, MD, 1992

Chair, Task Force on Hospital Outcomes, Carrier Foundation, 1993-1994

Director, Addiction Treatment Research and Medication Development Division, Center for Studies of Addiction, University of Pennsylvania, 1995 - Present

Researcher, Researchers in Residence Program, NIAAA, 2000 - 2001

Fellow, American Psychological Association, 2000 - Present

Member, Executive Committee, Center for Studies of Addiction, University of Pennsylvania,
2000 - Present
Advisor, Initiative on Managing Alcohol Problems in Primary Care Settings. Office of Managed Care
within the Center for Substance Abuse Treatment (CSAT), U.S. Department of Health and
Human Services 2000-2001
Expert, AAAS Eurekalert Expert Database, 2001 – Present
Member, Annenberg Substance Abuse in Adolescents Commission, 2003-Present
Member, Scientific Program Committee, Research Society on Alcoholism, 2003
Member, Vivitrex Writing Committee, 2003-Present
Member, Conference Planning Committee, Complexities of Co-Occurring Conditions,
June 23-25, 2004
Member of the Board, Bucks County Drug and Alcohol Commission, 2004

AWARDS AND HONORS

Phi Kappa Phi, 1972
Charles Etting Award in Recognition of Service to the University, Drexel University,
1973
The Outstanding Senior Award for Exceptional Contribution Through Leadership and
Service to the University, Drexel University, 1973
J. Peterson Ryder Award for Women in Recognition of Leadership, Drexel University,
1973
Fellowship for Graduate Training, The Medical College of Pennsylvania (now Allegheny
University for the Health Sciences), 1974-1975
Student Paper Award for High Scholarship and Outstanding Scientific Merit, American
Psychological Association, 1978
Who's Who in the East, 1983-Present
A. E. Bennett Award (Honorable Mention), Best Research Paper, Clinical Category,
Society of Biological Psychiatry, 1984
Who's Who in Science and New Frontiers, 1984-Present
The Directory of Distinguished Americans, 1984-Present
Who's Who in Gerontology, 1986-Present
World Who's Who in Women, 1986-Present
Henry B. Guze Award, Best Research Paper on Hypnosis, Society for Clinical and
Experimental Hypnosis, 1987
Who's Who in Emerging Leaders in America, 1987-Present
International Who's Who in Professional Business Women, 1989-Present
Elected into the John Morgan Society, University of Pennsylvania, 2002-Present
Caron Foundation Research Award, 2007

RESEARCH SUPPORT

American Society of Clinical Hypnosis Small Grant. Principal Investigator: 1980.
Physician Consumer Reports on ECT devices. Principal Investigator:
New Equipment Donations to Dr. Pettinati as part of this project:
MECTA Corporation, \$5200, 1985
Somatics, Incorporated, \$5950, 1985
MECTA Corporation, \$7900, 1986
Medcraft, Incorporated, \$7900, 1986
MECTA Corporation. Principal Investigator: 1985-1987 (\$5000)

National Institute of Mental Health. Co-Investigator, "Vasopressin to prevent memory loss with bilateral ECT" (MH40571-01A-1): 1985 (\$50,000)

Upjohn Mini-Grant. Principal Investigator: 1987 (\$5,000)

Bristol-Meyers. Co-Principal Investigator, double-blind clinical drug trial: 1987-1988 (\$100,000)

Simbec bioavailability study. Co-Principal Investigator: 1987-1988 (\$175,000).

Mead Johnson. Co-Principal Investigator, two double-blind clinical drug trials: 1987-1988 (\$150,000)

National Institute on Alcohol Abuse and Alcoholism/National Institute on Drug Abuse. Principal Investigator, "Cocaine & Alcohol: Inpatient vs. Outpatient Treatments" (R01 AA07831): 1988-1991 (\$610,000), 1991-1993 (Continuation Grant - \$310,000)

Pfizer Pharmaceuticals. Principal Investigator, two double-blind clinical drug trials: 1989-1994 (\$290,000)

National Institute on Alcohol Abuse and Alcoholism. Principal Investigator, "Fluoxetine & Cue Exposure to Reduce Alcohol Craving" Component #2 of Alcohol Research Center Grant, (P50 AA08747): 1991-1995 (\$950,000)

National Institute on Alcohol Abuse and Alcoholism. Principal Investigator, "Sertraline for Alcohol Dependence and Depression" (R01 AA09544): 1992-1998 (\$995,000)

National Institute of Mental Health. Principal Investigator, "Continuation Pharmacotherapy Following ECT" (R01 MH47709): 1992-1996 (\$750,000)

Janssen Research Foundation. Principal Investigator, two double-blind clinical drug trials: 1993-1995 (\$172,000)

UpJohn-Pharmacia Pharmaceuticals. Co-Principal Investigator, CDT device trial: 1997-1998 (\$200,000)

Pfizer Pharmaceuticals. Principal Investigator, double-blind clinical drug trial: 1997-1998 (\$200,000)

National Institute on Drug Abuse. Principal Investigator, "Naltrexone in Two Models of Psychosocial Treatments for Cocaine Dependence Complicated by Alcohol Abuse" Component #4 of Treatment Research Center Grant, (P60 DA 05186): 1997-2002, (\$2,105,000)

Lipha Pharmaceuticals. Co-Principal Investigator, double-blind clinical drug trial: 1997-1998.(\$200,000)

National Institute on Alcohol Abuse and Alcoholism. Principal Investigator, "Behavioral Support with Pharmacotherapy with Alcoholics" (U10 AA11768): 1997-2003 (\$1,350,000)

National Institute on Alcohol Abuse and Alcoholism. Co-Principal Investigator, "Naltrexone Treatment of Alcohol Dependence": 1998-2003 (\$2,725,000)

National Institute on Alcohol Abuse and Alcoholism. Principal Investigator, "Sertraline for Alcohol Dependence and Depression" (R01 AA09544): 1999-2004 (\$2,275,000)

National Institute on Drug Abuse. Center Director and Principal Investigator, "Innovative Approaches for Cocaine Pharmacotherapy" and "Two Medications, Disulfiram and Naltrexone, For the Treatment of Alcohol Dependence with Cocaine Dependence." Component #2 of Medication Development Center Grant (P50 DA 12756); 1999-2004 (\$919,519)

Oy Contral Pharma. Principal Investigator, Double-blind clinical trial: 2000-2001 (\$250,000).

Drug Abuse Sciences. Principal Investigator, Double-blind clinical trial: 2001 - 2002 (\$150,000).

Eli Lilly and Company, Principal Investigator, Double-blind clinical trial: 2001 - 2002 (\$150,000)

Alkermes, Inc. Principal Investigator, Double-blind clinical trial: 2002 - 2004 (\$290,300)

AstraZenca Pharmaceuticals, Principal Investigator, clinical trial: 2003-2004 (\$205,980)
Alkermes, Inc. Co-Principal Investigator, Naltrexone Depot clinical trial: 2003-2004 (\$264,096)
National Institute on Alcohol Abuse and Alcoholism. Principal Investigator, "Behavioral Support with Pharmacotherapy with Alcoholics" (U10 AA11768): 2003-2005 (\$764,668)
Bristol-Meyers Squibb, Principal Investigator, Double-blind clinical trial: 2004-2005 (\$297,817)
Ortho-McNeil Pharmaceuticals, Principal Investigator, Double-blind clinical trial: 2004-2005 (\$220,920)
National Institute on Drug Abuse. Center Director and Co- Investigator, "Innovative Approaches for Cocaine Pharmacotherapy" and "Topiramate for the Treatment of Cocaine and Alcohol Dependence." Component #1 of Medication Development Center Grant (P50 DA 12756); 2004-2009 (\$6,190,407)
AstraZenca Pharmaceuticals, Principal Investigator, Double-blind clinical trial: 2006-2007 (\$200,000)
Forest Pharmaceuticals, Principal Investigator, Double-blind clinical trial: 2006-2007 (\$150,000)
Forest Pharmaceuticals, Principal Investigator, Medication and placebo for a NIDA sponsored double-blind clinical trial at no cost: 2006-2007
National Institute on Alcohol Abuse and Alcoholism. Principal Investigator, "Double-blind, placebo-controlled, multi-site trial of quetiapine for the treatment of alcohol dependence": 2007-2009 (\$750,000)
Eli Lilly and Company, Principal Investigator, Protocol H9T-MC-NABJ(a) a phase 2 study of LY2196044 compared with naltrexone and placebo in the treatment of alcohol dependence: 2008 - 2009 (\$215,000)

PROFESSIONAL SOCIETIES

College on Problems of Drug Dependence
Research Society on Alcoholism
American Academy of Addiction Psychiatry
American Psychological Association (Fellow)

EDITORIAL AND CONSULTING APPOINTMENTS

Advisory Editor, *International Journal of Clinical and Experimental Hypnosis* (1982-Present)
Advisory Editor, *Convulsive Therapy* (1985-Present)
Series Co-Editor, Guilford Series in *Clinical and Experimental Hypnosis* (with Michael J. Diamond, Ph.D.) (1986-Present)
Advisor, *American Psychiatric Association Task Force on Treatment of Psychiatric Disorders* (1987-1989)
Advisor, *American Psychiatric Association, DSM-IV Study Group on Substance Abuse* (1989-1994)
Advisory Editor, *American Journal of Drug and Alcohol Abuse* (1991-Present)
Editorial Board Member, *Drug and Alcohol Dependence* (2001 - 2007)
Ad Hoc Reviewer, *Alcohol Health & Research World, American Journal of Psychiatry, Archives of General Psychiatry, Biological Psychiatry, Contemporary Psychology, Journal of Abnormal Psychology, Journal of Clinical Psychiatry, Journal of Studies on Alcohol, Neuropsychiatry, Neuropsychology, Drug and Alcohol Dependence, and Behavioral Neurology, Psychiatry Research*
Editor, COMBINE Methods Supplement, *Journal of Studies on Alcohol*, 2003-2005
Advisor, Vivtrex Marketing Group, 2003-2006

Advisor, Astrazeneca Consultant Panel, 2003-2006
Advisor, Titan, Inc. 2004
Advisor, Forest Pharmaceuticals, 2005
Advisor, Princeton House, Strategic Planning Committee, Princeton Medical Center, 2007.

MAJOR TEACHING AND CLINICAL RESPONSIBILITIES AT THE UNIVERSITY OF PENNSYLVANIA:

| | |
|-----------|---|
| 1995-1996 | Preceptor for postdoctoral fellow, Richard Saini, M.D. |
| 1996-1997 | Preceptor for postdoctoral fellow, Margaret Rukstalis, M.D. |
| 1997-1999 | Preceptor for postdoctoral fellow, Barbara Flannery, Ph.D. |
| 1998-2001 | Preceptor for postdoctoral fellow, John Monterosso, Ph.D. |
| 2004-2005 | Preceptor for postdoctoral fellow, Jesse Suh, Ph.D. |
| | Preceptor for postdoctoral fellow, Jennifer Lussier, Ph.D. |
| 2007-2008 | Preceptor for postdoctoral fellow, Jennifer Plebani, Ph.D. |

PUBLICATIONS

1. Pettinati, H. M. & Evans, F. J. (1978). Posthypnotic amnesia: Evaluation of selective recall of successful experiences. *International Journal of Clinical and Experimental Hypnosis*, 26, 317-329.
2. Pettinati, H. M. (1981). Following alcoholics for four years. *Carrier Foundation Letter*, 70, 1-4.
3. Pettinati, H. M., Evans, F. J., Orne, E. C., & Orne, M. T. (1981). Restricted use of success cues in retrieval during posthypnotic amnesia. *Journal of Abnormal Psychology*, 90, 345-353.
4. Pettinati, H. M. (1982). Measuring hypnotizability in psychotic patients. *International Journal of Clinical and Experimental Hypnosis*, 30, 404-416.
5. Pettinati, H. M. (1982). Review of electroconvulsive therapy: An appraisal by Robert L. Palmer (Ed.). *Journal of Psychosocial Nursing and Mental Health Services*, 20, 36-37.
6. Pettinati, H. M., Sugerman, A. A., DiDonato, N., & Maurer, H. S. (1982). The natural history of alcoholism over four years. *Journal of Studies on Alcohol*, 43, 201-215.
7. Pettinati, H. M., Sugerman, A. A., & Maurer, H. S. (1982). Four-year MMPI changes in abstinent and drinking alcoholics. *Alcoholism: Clinical and Experimental Research*, 6, 487-494.
8. Evans, F. J. & Pettinati, H. M. (1983). Hypnosis. *Carrier Foundation Letter*, 85, 1-4.
9. Pettinati, H. M., Sugerman, A. A., DiDonato, N., & Maurer, H. S. (1983). A four-year history of alcoholics after treatment. *Digest of Alcoholism Theory and Application*, 2, 30-39.
10. Herr, B. & Pettinati, H. M. (1984). Long-term outcome in working and homemaking alcoholic women. *Alcoholism: Clinical and Experimental Research*, 8, 576-579.

11. Horne, R. L., Pettinati, H. M., Menken, M., Sugerman, A. A., Varga, E., & Wilson, G. F. (1984). Dexamethasone in ECT: Efficacy for depression and post-ECT amnesia. *Biological Psychiatry*, *9*, 13-27.
12. Pettinati, H. M. & Bonner, K. M. (1984). Cognitive functioning in depressed, geriatric patients with a history of ECT. *American Journal of Psychiatry*, *141*, 49-52.
13. Pettinati, H. M. & Rosenberg, J. (1984). Memory self-ratings before and after electroconvulsive therapy: Depression vs. ECT-induced. *Biological Psychiatry*, *19*, 539-548.
14. Pettinati, H. M., Sugerman, A. A., & Maurer, H. (1984). Psychological changes in abstaining and drinking alcoholics. *Digest of Alcoholism Theory and Application*, *3*, 15-19.
15. Rosenberg, J. & Pettinati, H. M. (1984). Differential memory complaints after bilateral and unilateral electroconvulsive therapy. *American Journal of Psychiatry*, *141*, 1071-1074.
16. Horne, R. L., Pettinati, H. M., Sugerman, A. A., & Varga, E. (1985). Comparing bilateral to unilateral electroconvulsive therapy in a randomized study with EEG monitoring. *Archives of General Psychiatry*, *42*, 1087-1092.
17. Pettinati, H. M. & Brown, M. M. (1985). Assessing depression in evaluating memory impairment [Letter to the editor]. *Journal of the American Geriatrics Society*, *33*, 570-571.
18. Pettinati, H. M., Horne, R. L., & Staats, J. M. (1985). Hypnotizability in patients with anorexia nervosa and bulimia. *Archives of General Psychiatry*, *42*, 1014-1016.
19. Pettinati, H. M., Magee, M., & Mathisen, K. S. (1985). Memory complaints in depressed geriatric inpatients. *Annals of the New York Academy of Sciences*, *444*, 528-530.
20. Pettinati, H. M. & Nilsen, S. (1985). Missed and brief seizures during ECT: Differential response between unilateral and bilateral electrode placement. *Biological Psychiatry*, *20*, 506-514.
21. Nilsen, S. M., Willis, K. W., & Pettinati, H. M. (1986). Initial impression of two new brief pulse ECT machines. *Convulsive Therapy*, *2*, 43-54.
22. Pettinati, H. M. (1986). Hypnosis and patients with eating disorders: Mind over body? *Hypnosis*, *13*, 175-183.
23. Pettinati, H. M. (1986). Memory loss [Letter to the editor]. *Psychiatry '86*, February, 204.
24. Pettinati, H. M. (1986). Unilateral nondominant electrode placement: Safety and efficacy. In Shagass, C. et al. (Eds.), *Biological Psychiatry*, 1985. New York: Elsevier Science Publishing Co., Inc. (pp. 897-899).
25. Pettinati, H. & Fink, M. (1986). Different indications: Bilateral vs. unilateral ECT [News and Notes]. *Convulsive Therapy*, *2*, 217-219.

26. Pettinati, H. M., Mathisen, K. S., Rosenberg, J., & Lynch, J. F. (1986). Meta-analytical approach to reconciling discrepancies in efficacy between bilateral and unilateral ECT. *Convulsive Therapy*, 2, 7-17.
27. Pettinati, H. M. & Wade, J. H. (1986). Hypnosis in the treatment of anorexic and bulimic patients. *Seminars in Adolescent Medicine*, 2, 75-79.
28. Mathisen, K. S. & Pettinati, H. M. (1987). Meta-analytic evaluation of ECT [Letter to the editor]. *Convulsive Therapy*, 3, 69-70.
29. Pettinati, H. M., Franks, V., Wade, J. H., & Kogan, L. G. (1987). Distinguishing the role of eating disturbance from depression in the sex role self-perceptions of anorexic and bulimic inpatients. *Journal of Abnormal Psychology*, 96, 280-282.
30. Pettinati, H. M. & Nilsen, S. M. (1987). Increased incidence of missed seizures during ECT in the elderly male. *Convulsive Therapy*, 3, 26-30.
31. Kight-Law, A., Sugerman, A. A., & Pettinati, H. M. (1988). An application of an MMPI classification system for predicting outcome in a small clinical sample of alcoholics. *American Journal of Drug and Alcohol Abuse*, 14, 325-334.
32. Pettinati, H. M. (Ed.). (1988). *Hypnosis and Memory*. New York: Guilford Press.
33. Pettinati, H. M. (1988). Integrative summary and future directions: Hypnosis and memory. In Pettinati, H. M. (Ed.), *Hypnosis and Memory* (pp. 277-291). New York: Guilford Press.
34. Dritschel, B. H. & Pettinati, H. M. (1989). The role of female occupation in severity of alcohol-related problems. *American Journal of Drug and Alcohol Abuse*, 15, 61-72.
35. Mattes, J. A., Pettinati, H. M., Nilsen, S., Robin, S. E., & Willis, K. W. (1989). Vasopressin for ECT induced memory impairment: A placebo-controlled comparison. *Psychopharmacology Bulletin*, 25, 80-84.
36. Pettinati, H. M., Kogan, L. G., Margolis, C., Shrier, L., & Wade, J. H. (1989). Hypnosis, hypnotizability and the bulimic patient. In E. K. Baker & L. M. Hornyak (Eds.), *Handbook of Experimental Techniques in the Treatment of Eating Disorders*. New York: Guilford Press. (pp. 34-59).
37. Mattes, J. A., Pettinati, H. M., Stephens, S., Robin, S. E., & Willis, K. W. (1990). A placebo-controlled evaluation of vasopressin for ECT-induced memory impairment. *Biological Psychiatry*, 27, 289-303.
38. Pettinati, H. M., Kogan, L. G., Evans, F. J., Wade, J. H., Horne, L. R., & Staats, J. M. (1990). Hypnotizability of psychiatric inpatients according to two different scales. *American Journal of Psychiatry*, 147, 69-75.
39. Pettinati, H. M., Stephens, S., Willis, K. W., & Robin, S. E. (1990). Evidence for less improvement in depression in patients taking benzodiazepines during unilateral ECT. *American Journal of Psychiatry*, 147, 1029-1035.

40. Stephens, S. N., Pettinati, H. M., Willis, K. W., Bedient, L., Greenberg, R. M., & Zomorodi, A. (1990). Clinical review of Medcraft Corporation's new brief-pulse ECT device. *Convulsive Therapy*, 6, 42-53.
41. Pettinati, H. M. (1991). Diagnosing personality disorders in substance abusers. *NIDA Research Monograph: Problems of Drug Dependence 1990*, 105, 236-242.
42. Stephens, S. N., Greenberg, R. M., & Pettinati, H. M. (1991). Choosing an ECT device. *Psychiatric Clinics of North America*, 14(4), 989-1006.
43. McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992). The fifth edition of the Addiction Severity Index. *Journal of Substance Abuse Treatment*, 9, 199-213.
44. Greenberg, R. M. & Pettinati, H. M. (1993). Benzodiazepines and ECT. *Convulsive Therapy*, 9(4), 262-273.
45. Pettinati, H. M., Meyers, K., Jensen, J. M., Kaplan, F., & Evans, B. D. (1993). Inpatient vs. outpatient treatment for substance dependence revisited [Special issue]. Contemporary topics in drug dependence and alcoholism. *Psychiatric Quarterly*, 64(2), 173-182.
46. Stephens, S. M., Pettinati, H. M., Greenberg, R. M., & Kelly, C. E. (1993). Continuation and maintenance therapy with outpatient ECT. In C. E. Coffey (Ed.), *The Clinical Science of Electroconvulsive Therapy*. Washington, D.C.: American Psychiatric Association Press. (pp. 143-164).
47. Pettinati, H. M. (1994). Measuring clinical outcomes. *Insights*, 15.
48. Pettinati, H. M. (1994). Speed of ECT [Letter to the editor]. *Convulsive Therapy* 10(1), 69-73.
49. Pettinati, H. M. & Abraham, G. S. (1994). Clinical treatment of addiction [Review of Handbook for assessing and treating addictive disorders]. *Contemporary Psychology*, 39, 510-511.
50. Pettinati, H. M., Tamburello, T. A., Ruetsch, C. R., & Kaplan, F. N. (1994). Patient attitudes toward electroconvulsive therapy. *Psychopharmacology Bulletin*, 30(3), 471-475.
51. Meyers, K., McLellan, A. T., Jaeger, J., & Pettinati, H. M. (1995). The development of the *Comprehensive Addiction Severity Index for Adolescents (CASI-A)*: An interview for assessing multiple problems of adolescents. *Journal of Substance Abuse Treatment*, 12(3), 181-193.
52. Berg, B., Pettinati, H. M., & Volpicelli, J. R. (1996). Risk-benefit assessment of naltrexone for the treatment of alcohol dependence. *Drug Safety*, 15(4), 274-282.
53. Johnson, B. A., Jasinski, D. R., Galloway, G., Kranzler, H., Weinrieb, R., Anton, R. F., Mason, B. J., Bohn, M. J., Pettinati, H. M., Rawson, R., Urshel, H. C., & Clyde, C. (1996). Ritanserin in the treatment of alcohol dependence: A multi-center clinical trial. *Psychopharmacology*, 128, 206-215.

54. Mulsant, B., Prudic, J., Haskett, R., Mann, J. J., Pettinati, H. M., & Sackeim, H. A. (1996). Determinants of acute response to ECT in younger vs older patients. *American Journal of Geriatric Psychiatry*, 4(4), 372.
55. Pettinati, H. M. (1996). Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence. *Alcoholism: Clinical and Experimental Research(Supplement)*, 20(7), 23A-29A.
56. Pettinati, H. M. & Belden, P. P. (1996). Ambulante versus stationäre therapie bei abhangigkeitserkrankungen: Neue perspektiven.[Inpatient vs. outpatient treatment for addictive disorders: New perspectives.] In K. Mann & G. Buchkremer (Eds.), *Sucht: Grundlagen, diagnostik, therapie [Future of Addiction Research]*. Tubingen, Germany: Gustav Fischer. (pp. 265-273).
57. Pettinati, H. M., Belden, P. P., Evans, B. D., Ruetsch, C. R., Meyer, K., & Jensen, J. M. (1996). The natural history of outpatient alcohol and drug abuse treatment in a private health care setting. *Alcoholism: Clinical and Experimental Research*, 20(5), 847-852.
58. Prudic, J., Haskett, R., Mulsant, B., Malone, K. M., Pettinati, H. M., Stephens, S., Greenberg, R., Rifas, S. L., & Sackeim, H. A. (1996). Resistance to antidepressant medications and short-term clinical response to electroconvulsive therapy. *American Journal of Psychiatry*, 153(8), 985-992.
59. Kranzler, H. R., Mason, B. J., Pettinati, H. M., & Anton, R. F. (1997). Methodological issues in pharmacotherapy trials with alcoholics. In M. Hertzman & D. Faltner (Eds.), *The Handbook of Psychopharmacology Trials*. New York: New York University Press. (pp. 213-245).
60. Mulsant, B., Haskett, R., Prudic, J., Thase, A., Malone, K. M., Mann, J. J., Pettinati, H. M., & Sackeim, H. A. (1997). Low use of neuroleptic drugs in the pharmacologic treatment of psychotic major depression. *American Journal of Psychiatry*, 154(4), 559-561.
61. Pettinati, H. M., Pierce, J. D., Wolf, A. L., Rukstalis, M. R., & O'Brien, C. P. (1997). Gender differences in comorbidly depressed alcohol dependent outpatients. *Alcoholism: Clinical and Experimental Research*, 21(9), 1742-1746.
62. Saini, R. S., Pettinati, H. M., Semwanga, A. E., & O'Brien, C. P. (1997). Carbohydrate-deficient transferrin: An investigative biochemical marker of heavy alcohol consumption. *Psychopharmacology Bulletin*, 33(1), 171-175.
63. Gariti, P., Alterman, A., Ehrman, R., & Pettinati, H. (1998). Reliability and validity of the aggregate method of determining cigarettes smoked per day estimating cigarettes smoked per day: Aggregate and timeline follow-back. *American Journal on Addictions*, 7(4), 283-287.
64. Oslin, D., Pettinati, H., Luck, G., Semwanga, A., Cnaan, A., & O'Brien, C.P. (1998). Clinical correlations with CDT levels in women with alcoholism. *Alcoholism: Clinical and Experimental Research*, 22(9), 1981-1985.
65. Flannery, B., Volpicelli, J., & Pettinati, H. (1999). Psychometric properties of the Penn Alcohol Craving Scale. *Alcoholism: Clinical and Experimental Research*, 23(8) 1289-1295.

66. Kampman, K.K., Rukstalis, M.R., Ehrman, R., McGinnis, D.E., Gariti, P., Volpicelli, J.R., Pettinati, H.M., & O'Brien, C.P. (1999). Open trials as a method of prioritizing medications for inclusion in controlled trials for cocaine dependence. *Addictive Behaviors, 24*(2), 287-291.
67. Oslin, D., Pettinati, H., Volpicelli, J., Wolf, A., Kampman, K., & O'Brien, C.P. (1999). The effects of naltrexone on alcohol and cocaine use in dually addicted patients. *Journal of Substance Abuse Treatment, 16*(2), 163-167.
68. Pettinati, H., Meyers, K., Evans, B.D., Ruetsch, C.R., Kaplan, F.N., Jensen, J.M., & Hadley, T.R. (1999). Inpatient alcohol treatment in a private healthcare setting: Which patients benefit and at what cost? *American Journal on Addictions, 8*, 220-233.
69. Pettinati, H., Pierce, J., Meyers, K. & Belden, P. (1999). The relationship of Axis II disorders to other known predictors of addiction to treatment outcomes. *American Journal on Addictions, 8*, 136-147.
70. Kampman, K.K., Rukstalis M.R., Pettinati, H.M., Muller, E., Acosta, T., Gariti, P., Ehrman, R., & O'Brien, C.P. (2000). The combination of phentermine and fenfluramine reduced cocaine withdrawal symptoms in an open trial. *Journal of Substance Abuse Treatment, 19*(1), 77-79.
71. Pettinati, H., Oslin, D., & Decker, K. (2000). Role of serotonin and serotonin selective pharmacotherapy in alcohol dependence. *CNS Spectrums, 5*(2), 33-46.
72. Pettinati, H.M., Rukstalis, M.R., Luck, G.J., Volpicelli, J.R., & O'Brien, C.P. (2000). Gender and psychiatric comorbidity: Impact on clinical presentation of alcohol dependence. *American Journal on Addictions, 9*, 242-252.
73. Pettinati, H.M., Volpicelli, J.R., Kranzler, H.R., Luck, G., Rukstalis, M.R., & Cnaan, A. (2000). Sertraline treatment for alcohol dependence: Interactive effects of medication and subtype. *Alcoholism: Clinical and Experimental Research, 24*(7), 1041-1049.
74. Pettinati, H., Volpicelli, J., Pierce, J., & O'Brien, C. (2000). Improving naltrexone response: An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. *Journal of Addictive Diseases, 19* (1), 71-83
75. Sackeim, H., Haskett, R., Mulsant, B., Thase, M., Mann, J., Pettinati, H.M., Greenberg, R., Crowe, R. R. , Cooper, T. B., & Prudic, J. (2000). Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy. A randomized controlled trial. *Journal of the American Medical Association, 285* (10), 1299-1307.
76. Anton, R.F., Dominick, C., Bigelow, M., Westby, C., & CDTEch Study Group. (2001) Comparison of Bio-Rad %CDT TIA and CDTEct as laboratory markers of heavy alcohol use and their relationships with g-glutamyltransferase. *Clinical Chemistry, 47*, 1769-1775.
77. Monterosso, J., Flannery, B., Pettinati, H.M., Oslin, D., Rukstalis, M.R., O'Brien, C.P., & Volpicelli, J.R. (2001). Predicting treatment response to naltrexone: The influence of craving and family history. *American Journal on Addictions, 10*(3), 258:268.

78. Pettinati, H.M. (2001). The use of selective serotonin reuptake inhibitors (SSRIs) in treating alcohol subtypes. *Journal of Clinical Psychiatry*, 62, Supplement 20, 26-31.
79. Pettinati, H.M., Volpicelli, J.R., Luck, G., Kranzler, H., Rukstalis, M., & Cnaan, A. (2001). Double-blind clinical trial of sertraline treatment for alcohol dependence. *Journal of Clinical Psychopharmacology*, 21(2), 143-153.
80. Volpicelli, J.R., Pettinati, H.M., McLellan, A.T., & O'Brien, C.P. (2001). *Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach*. New York: Guilford Press.
81. Anton, R.F., Lieber, C., Tabakoff, B. for the CDTest Study Group. (2002). Carbohydrate deficient transferrin (CDT) and gamma-glutamyltransferase for the detection and monitoring of alcoholics. Results from a multi-site study. *Alcoholism: Clinical and Experimental Research*, 26(8), 1215-1222.
82. Flannery, B.A., Allen, J.P., Pettinati, H.M., Rohsenow, D.J., & Cisler, R.A. (2002). Using acquired knowledge and new technologies in alcoholism treatment trials. *Alcoholism: Clinical and Experimental Research*, 26(3), 423-429.
83. Kampman, K.M., Volpicelli, J.R., Mulvaney, F., Rukstalis, M.R., Alterman, A.I., Pettinati, H.M., Weinrieb, R.W. & O'Brien, C.P. (2002). Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. *Addictive Behaviors*, 27, 251-260.
84. Kampman, K.M., Pettinati, H.M., Volpicelli, J.R., Kaempf, G., Turk, E., Insua, A., Lipkin, C., Sparkman, T., & O'Brien, C.P. (2002). Concurrent cocaine withdrawal alters alcohol withdrawal symptoms. *Journal of Addictive Diseases*, 21(4), 13-26.
85. McKay, J.R., Pettinati, H.M., Morrison, R., Feeley, M., Mulvaney, F., & Gallop, R. (2002). Relation of depression diagnoses to 2-Year outcomes in cocaine dependent patients in a randomized continuing care study. *Psychology of Addictive Behaviors*, 16(3), 225-235.
86. Oslin, D.W., Pettinati, H., & Volpicelli, J.R. (2002). Alcoholism treatment adherence: Older age predicts better adherence and drinking outcomes. *American Journal of Geriatric Psychiatry*, 10(6), 740-747.
87. Rukstalis, M.R., Lynch, K., Oslin, D., Pettinati, H.M., Anderson, S.A., Volpicelli, J.R., & Anton, R. (2002). Carbohydrate deficient transferrin levels reflect heavy drinking in alcohol dependent women seeking treatment. *Alcoholism: Clinical and Experimental Research*, 26(10), 1539-1544.
88. Kampman, K., Pettinati, H., Lynch, K.G., Sparkman, T., & O'Brien, C. (2003). A pilot trial of olanzapine in the treatment of cocaine dependence. *Drug and Alcohol Dependence*, 70(3), 265-273.
89. McKay, J.R., Lynch, K., Pettinati, H., & Shepard, D. (2003). An examination of gender and race effects in a study of continuing care for alcohol and cocaine dependent patients. *Alcoholism: Clinical and Experimental Research*, 27(8), 1321-1323.

90. Nellissery, M., Feinn, R.S., Covault, J., Gelernter, J., Anton, R., Pettinati, H., Moak, D., Mueller, T., & Kranzler, H. (2003). Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics. *Alcoholism: Clinical and Experimental Research*, 27(9):1406-1408.
91. Oslin, D.W., Berrettini, W., Kranzler, H.R., Pettinati, H.M., Gelernter, J., Volpicelli, J.R., O'Brien, C.P. (2003). A functional polymorphism of the mu-opioid receptor gene is associated with therapeutic response in alcohol dependent patients treated with naltrexone. *Neuropsychopharmacology*, 28,1546-1552.
92. Pettinati, H.M., Kranzler, H., & Madaras, J. (2003). The status of serotonin-selective medications in the treatment of alcohol dependence. In Galanter, M. (Ed), *Recent Developments in Alcoholism*. (pp. 247-262).
93. Pettinati, H.M., Monterosso, J., Lipkin, C., & Volpicelli, J.R. (2003). Patient attitudes toward treatment predict attendance in clinical pharmacotherapy. *American Journal on Addictions*; 12, 324-335.
94. Pettinati, H.M., Weiss, R., & Madaras, J. (2003). Models for integrating psychotherapeutic and pharmacological interventions. In Johnson, B.A., Ruiz, P., & Galanter, M. (Eds), *Alcoholism: A Practical Handbook*. Baltimore: Lippincott, Williams & Wilkins. (pp. 131-154).
95. The COMBINE Study Research Group. (2003). Testing combined pharmacotherapies and behavioral interventions in alcohol dependence (The COMBINE study): A pilot feasibility study. *Alcoholism: Clinical and Experimental Research*, 27, 1123-1131.
96. The COMBINE Study Research Group. (2003). Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: Rational and methods. *Alcoholism: Clinical and Experimental Research*, 27, 1107-1122.
97. Anton, R.F., Pettinati, H., Zweben, A., Kranzler, H., Johnson, B., Bohn, M., McCaul, M.E., Anthenelli, R., Salloum, I., Galloway, G., Garbutt, J., Swift, R., Gastfriend, G.H., Kallio, A., & Karhuvaara, S. (2004). A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. *Journal of Clinical Psychopharmacology*, 24(4), 421-428.
98. Covault, J., Pettinati, H., Moak, D., Mueller, T., & Kranzler, H. (2004). Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema. *American Journal of Medical Genetics: Part B Neuropsychiatric Genetics*, 127B(1), 42-47.
99. Dundon, W., Lynch, K.G., Pettinati, H.M. & Lipkin, C. (2004). Treatment outcomes in Type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. *Alcoholism: Clinical and Experimental Research*, 28(7), 1065-1073.
100. Kampman, K., Pettinati, H.M., Lynch, K.G., Dackis, C., Sparkman, T., Weigley, C., & O'Brien, C.P. (2004). A pilot trial of topiramate for the treatment of cocaine dependence. *Drug and Alcohol Dependence*, 75, 233-240.

101. Kampman, K.M., Pettinati, H.M, Volpicelli, J.R., Oslin, D.M., Lipkin, C., Sparkman, T., & O'Brien, C.P. (2004). Cocaine dependence severity predicts outcome in outpatient detoxification from cocaine and alcohol. *American Journal on Addictions, 13*, 74-82.
102. Kranzler, H.R., Wesson, D.R., Billot, L. & the DAS Naltrexone Study Group. (2004). Naltrexone depot for treatment of alcohol dependence: A multi-center, randomized, placebo-controlled clinical trial. *Alcoholism: Clinical and Experimental Research, 28*(7), 1051-1059.
103. McKay, J.R., Lynch, K.G., Shepard, D.S., Ratichek, S., Morrison, R., Koppenhaver, J. & Pettinati, H.M. (2004). The effectiveness of telephone continuing care in the clinical management of alcohol and cocaine substance use disorders: 12-month outcomes. *Journal of Consulting and Clinical Psychology, 17*, (6):967-979.
104. O'Brien, C.P., Charney, D.S., Lewis, L., et al (2004). Priority actions to improve the care of persons with co-occurring substance use and other mental disorders: A call to action. *Biological Psychiatry, 56*(10), 703-713.
105. Pettinati, H.M. (2004) Antidepressant treatment of co-occurring depression and alcohol dependence. *Biological Psychiatry, 56*,785-792.
106. Pettinati, H.M., Dundon, W.D. & Lipkin, C. (2004). Gender differences in response to sertraline pharmacotherapy in type A alcohol dependence. *American Journal on Addictions, 13*, 236-247.
107. Pettinati, H.M., Weiss, R.D., Miller, W.R., Donovan, D., Ernst, D.B., & Rounsaville, B.J. (2004). COMBINE Monograph Series, Volume 2. *Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence*. DHHS Publication. No (NIH) 04-5289. Bethesda, MD: NIAAA.
108. Commission on Adolescent Substance and Alcohol Abuse. (2005) Substance Use Disorders. In D.L. Evans, E.B. Foa, R.E. Gur, H. Hendin, C.P. O'Brien, M.E.P. Seligman, & B.T. Walsh (Eds), *Treating and Preventing Adolescent Mental Health Disorders*. New York: Oxford University Press.
109. Dackis, C., Kampman, K., Lynch, K., Pettinati, H. & O'Brien, C.P. (2005). A double-blind, placebo-controlled trial of modafinil for cocaine dependence. *Neuropsychopharmacology 30*, 205-211.
110. Dackis, C., Lynch, K., Kampman, K., Pettinati, H., & O'Brien, C. (2005). Response to letter to the editor: Do self-reports reliably assess abstinence in cocaine dependent patients? *Neuropsychopharmacology, 30*(12): 2299-2300.
111. Garbutt, J.C., Kranzler, H.R., O'Malley, S. S., Gastfriend, D. R., Pettinati, H. M., Silverman, B. L., Loewy, J. W., Ehrich, E. W. for the Vivitrex Study Group. (2005). Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. *JAMA, 293*(13), 1617-1625.

112. Garbutt, J.C., Kranzler, H.R., O'Malley, S. S., Gastfriend, D. R., Silverman, B. L., Loewy, J. W., Ehrich, E. W., & Pettinati, H. M. (2005). Naltrexone treatment for alcohol dependence – Reply. *JAMA*, 24 (31), 294:900.
113. McKay, J.R., Lynch, K.G. Shepherd, D.S. & Pettinati, H.M. (2005). The effectiveness of telephone-based continuing care for alcohol and cocaine dependence. *Archives of General Psychiatry*, 62, 199-207.
114. O'Brien, C.P., Pettinati, H.M., & Oslin, D.W. (2005). Naltrexone: Clinical data. In R. Spanagel and K.F. Mann (Eds), *Drugs for Relapse Prevention of Alcoholism*. Basel, Switzerland: Birkhauser Verlag. (pp. 59-72).
115. Pettinati, H.M. (2005). Recent advances in treatment. *Psychiatric Times*, 22(2), 1-2.
116. Pettinati, H.M. & Rabinowitz, A.R. (2005). Recent advances in the treatment of alcoholism. *Clinical Neuroscience Research*, 5(2-4), 151-159.
117. Pettinati, H.M., Weiss, R.D., Dundon, W., Miller, W.R., Donovan, D., Ernst, D.B., & Rounsaville, B.J. (2005). A structured approach to medical management: A psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. *Journal of Studies on Alcohol, Supplement 15*, 170-178.
118. Pettinati, H.M., Zweben, A., & Mattson, M.E. (Eds.) (2005). The COMBINE Study: Conceptual, Methodological and Practical Issues in a Clinical Trial that Combined Medications and Behavioral Treatments. *Journal of Studies on Alcohol, Supplement 15*.
119. Swift, R., & Pettinati, H.M. (2005). Choosing pharmacotherapies for the COMBINE study--process and procedures: An investigational approach to combination pharmacotherapy for the treatment of alcohol dependence. *Journal of Studies on Alcohol, Supplement 15*, 141-147.
120. Anton, R.F., O'Malley, S.S., Ciraulo, D.A., Cisler, R.A., Couper, D., Donovan, D.M., Gastfriend, D.R., Hosking, J.D., Johnson, B.A., LoCastro, J.S., Longabaugh, R., Mason, B.J., Mattson, M.E., Miller, W.R., Pettinati, H.M., Randall, C.L., Swift, R., Weiss, R.D., Williams, L.D., Zweben, A. for the COMBINE Study Research Group. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: The combine study: A randomized controlled trial. *JAMA*, 295 (17), 2003-2017.
121. Kampman, K.M., Dackis, C., Lynch, K.G., Pettinati, H., Tirado, C., Gariti, P., Sparkman, T., Atzram, M., & O'Brien, C.P. (2006). A double-blind, placebo-controlled trial of amantadine, propranolol and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. *Drug and Alcohol Dependence*, 85(2), 129-137.
122. Kranzler, H., Mueller, T., Cornelius, J., Pettinati, H.M., Moak, D., Martin, P. R., Anthenelli, R., Brower, K. J., O'Malley, S., Mason, B.J., Hasin, D., & Keller, M. (2006). Sertraline treatment of co-occurring alcohol dependence and major depression. *Journal of Clinical Psychopharmacology*, 26, 1-8.
123. Pettinati, H.M. (2006). Improving medication adherence in alcohol dependence. *Journal of Clinical Psychiatry*, 67 (Supplement 14), 23-30.

124. Pettinati, H.M., Anton, R.F., & Willenbring, M. L. (2006). The COMBINE study: An overview of the largest pharmacotherapy study to date for treating alcohol dependence. *Psychiatry* 2006, 3(10), 36-39.
125. Pettinati, H.M., O'Brien, C.P., Rabinowitz, A.R, Wortman, S.M, Oslin, D.W., Kampman, K.M., Dackis, C.A. (2006). The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. *Journal of Clinical Psychopharmacology*, 26(6), 610-625.
126. Pettinati, H.M. & Rabinowitz, A. R. (2006). Choosing the right medication for the treatment of alcoholism. *Current Psychiatry Reports*, 8 (5), 383-388.
127. Pettinati, H.M. & Rabinowitz, A.R. (2006). New pharmacotherapies for treating neurobiology of alcohol and drug addiction. *Psychiatry* 2006, 3(5) 14-16.
128. Suh, J. J., Pettinati, H. M., Kampman, K. M., O'Brien, C. P. (2006). The status of disulfiram. A half of a century later. *Journal of Clinical Psychopharmacology*, 26(3), 290-302.
129. Gastfriend, D.R., Garbutt, J.C., Pettinati, H.M., & Forman, R.F. (2007). Reduction in heavy drinking as a treatment outcome in alcohol dependence. *Journal of Substance Abuse Treatment*, 33, 71-80.
130. Johnson, B.A., Rosenthal, N., Capece, J.A., Wiegand, F., Mao, L., Beyers, K., McKay, A., Ait-Daoud, N., Anton, R.F., Ciraulo, D.A., Kranzler, H.R., Mann, K., O'Malley, S.S., Swift, R.M., for the Topiramate for Alcoholism Advisory Board, and the Topiramate for Alcoholism Study Group. (2007). Topiramate for treating alcohol dependence; *JAMA*, 298(14), 1641-1656.
131. Kampman, K.M., Pettinati, H.M., Lynch, K.G., Whittingham, T., Macfadden, W., Dackis, C., Tirado, C., Oslin, D.W., Sparkman, T. & O'Brien, C.P. (2007). A double-blind, placebo-controlled pilot trial of quetiapine in the treatment of Type A and Type B alcoholism. *Journal of Psychopharmacology*, 27, 344-351.
132. Pettinati, H.M. (2007). Letter to the Editor in regard to Timko, DeBenedetti, Moos and Moos (2006): "Predictors of 16-year mortality among individuals initiating help-seeking for an alcoholic use disorder". *Alcoholism: Clinical and Experimental Research*, 31(3), 512.
133. Pettinati, H.M. & Gallis, T. (2007). Advances and challenges in treating alcohol dependence with pharmacotherapy. *Psychiatric Times*, CMEducator, 68-71.
134. Suh, J.J., Gallis, T., Kampman, K.M., & Pettinati, H.M. (2007). Reply to Comments by Dr. Beresford on "The status of disulfiram: A half century later." *Journal of Psychopharmacology*, 27(4), 417-418.
135. Amhadi, J., Kampman, K., Dackis, C., Sparkman, T., & Pettinati, H.M. (2008). Cocaine withdrawal symptoms identify Type B "cocaine" dependent patients. *The American Journal on Addictions*, 17, 60-64.
136. Anton, R.F., Oroszi, G., O'Malley, S., Couper, D., Swift, R., Pettinati, H.M., & Goldman, D. (2008). An evaluation of u-opioid receptor (*OPRM1*) as a predictor of naltrexone response in the

treatment of alcohol dependence: Results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) Study. *Archives of General Psychiatry*, 65(2),135-144.

137. Ciraulo, D.A., Dong, Q., Silverman, B.L., Gastfriend, D.R., & Pettinati, H.M. (2008). Early treatment response in alcohol dependence with extended-release naltrexone. *Journal of Clinical Psychiatry*, 69, 190-195.
138. Donovan, D.M., Anton, R.F., Miller, W., Longabaugh, R., Hosking, J.D., & Youngblood, M., for the COMBINE Study Research Group. (2008). Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): Examination of post-treatment drinking outcomes. *Journal on Studies of Alcohol and Drugs*, 69, 5-13.
139. Dundon, W.D., Pettinati, H. M., Lynch, K. G., Xie, H., Varillo, K.M., Makadon, C., & Oslin, D. W. (2008). The therapeutic alliance in medical-based interventions impacts outcomes in treating alcohol dependence. *Drug and Alcohol Dependence*, 95, 230-236.
140. Ernst, D.B., Pettinati, H.M., Weiss, R.D., Donovan, D.M., & Longabaugh, R. (2008). An intervention for treating alcohol dependence: Relating elements of medical management to patient outcomes with implications for primary care. *Annals of Family Medicine*, 6(5), 435-440.
141. Johnson, B.A., Rosenthal, N., Capece, J.A., Weigand, F., Mao, L., Beyers, K., McKay, A., Ait-Daoud, N., Addolorato, G., Anton, R.F., Ciraulo, D.A., Kranzler, H.R., Mann, K., O'Malley, S.S., Swift, R.M., & the Topiramate for Alcoholism Study Group. (2008). Improvement of physical health and quality of life of alcohol dependent individuals with topiramate treatment. *Archives of Internal Medicine*, 168(11), 1188-1199.
142. Lohoff, F.W., Bloch, P.J., Weller, A.E., Nall, A.H., Doyle, G.A., Buono, R.J., Ferraro, T.N., Kampman, K.M., Pettinati, H.M., Dackis, C.A., Oslin, D.W., O'Brien, C.P., & Berrettini, W.H. (2008). Genetic variants in the cocaine- and amphetamine-regulated transcript gene (CARTPT) and cocaine dependence. *Neuroscience Letters*, 440(3), 280-283.
143. Lohoff, F.W., Weller, A.E., Bloch, P.J., Nall, A.H., Ferraro, T.N., Kampman, K.M., Pettinati, H.M., Oslin, D.W., Dackis, C.A., O'Brien, C.P., & Berrettini, W. (2008). Association between the catechol-O-methyltransferase (COMT) Val158Met polymorphism and cocaine dependence. *Neuropsychopharmacology*, 33, 3078–3084.
144. Oslin, D.W., Lynch, K.G., Pettinati, H.M., Kampman, K.M., Gariti, P., Gelfand, L., Ten Have, T., Wortman, S., Dundon, W., Dackis, C., Volpicelli, J.R., & O'Brien, C.P.. (2008). A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. *Alcohol Clinical and Experimental Research*, 32(7), 1299-1308.
145. Pettinati, H.M., Kampman, K.M., Lynch, K.G., Suh, J.J., Dackis, C.A., Oslin, D.W., & O'Brien, C.P. (2008). Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. *Journal of Substance Abuse Treatment*, 34, 378-390.
146. Pettinati, H.M., Kampman, K.M., Lynch K.G., Xie, H., Dackis, C., Rabinowitz, A.R., & O'Brien, C.P. (2008). A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. *Addictive Behaviors* 33, 651-667.

147. Suh, J.J., Pettinati, H.M., Kampman, K.M., & O'Brien, C.P. (2008). Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. *American Journal on Addictions, 17*, 463-468.
148. Zweben, A., Pettinati, H.M., Weiss, R.D., Youngblood, M., Cox, C.E., Mattson, M.E., Gorroochurn, P., & Ciraulo, D. (2008). Relationship between medication adherence and treatment outcomes: The COMBINE Study. *Alcoholism: Clinical and Experimental Research, 32*(9), 1-9.
149. Weiss, R.D., O'Malley, S.S., Hosking, J.D., LoCastro, J.S., Swift, R., for the COMBINE Study Research Group. (2008). Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study*. *Journal of Studies on Alcohol and Drugs, 69*, 878-884.
150. Ahmadi J, Kampman KM, Oslin DM, Pettinati HM, Dackis C, Sparkman T. (2009). Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment. *American Journal of Addictions, 18*, 81-86.
151. Anton, R.F., Oroszi, G., O'Malley, S., Couper, D., Swift, R., Pettinati, H.M., & Goldman, D. (2009). Response to the Letter to the Editor. *Archives of General Psychiatry.*
152. Bloch, P.J., Nall, A.H., Weller, A.E., Ferraro, T.N., Berrettini, W.H., Kampman, K.M., Pettinati, H.M., Dackis, C.A., O'Brien, C.P., Oslin, D.W., & Lohoff, F.W. (2009). Association analysis between polymorphisms in dopamine D3 receptor (*DRD3*) gene and cocaine dependence.
153. Lohoff, F.W., Bloch, P.J., Ferraro, T.N., Berrettini, W.H., Pettinati, H.M., Dackis, C.A., O'Brien, C.P., Kampman, K.M., & Oslin, D.W. (2009). Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (*CDNF*) gene and cocaine dependence. *Neuroscience Letters, 453*, 199-203.
154. Oroszi, G., Anton, R.F., O'Malley, S., Swift, R., Pettinati, H., Couper, D., Yuan, Q., & Goldman, D. (2009). *OPRM1* Asn40Asp predicts response to naltrexone: A haplotype-based approach. *Alcoholism: Clinical and Experimental Research, 33*(3), 383-393.
155. Pettinati, H.M., Gastfriend, D.R., Dong, Q., Kranzler, H.R., & O'Malley, S. (2009). Effect of extended release naltrexone (XR-NTX) on quality of life in alcohol dependent patients. *Alcoholism: Clinical and Experimental Research, 33*(2), 350-356.
156. Pettinati, H.M. & Plebani, J.G. (2009). Depression and substance use disorders in women. In: Brady, K. et al (eds) *Women and Addiction: A Comprehensive Handbook*. New York: Guilford Press.